Kyverna to present positive KYSA-8 data at MSToronto2026
Kyverna Therapeutics says it will present updated trial data in stiff person syndrome and progressive multiple sclerosis at MSToronto2026, including one-year KYSA-8 results from its KYSA-8 registrational trial and Phase 1 investigator-initiated trial data.
Story updates
12:07:30 PM UTC
SquawkNews
Kyverna will present full 1-year results from its KYSA-8 registrational SPS trial and updated Phase 1 MS data at MSToronto2026, and said it expects to complete its rolling BLA for miv-cel in SPS this quarter.Material DetailsContext by AI AnalystThis is late-stage confirmation signaling an imminent…